

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/523,333		
		Filing Date	January 28, 2005		
		First Named Inventor	Karl Lintner		
		Art Unit	N/A 1055		
		Examiner Name	Not Yet Assigned Amy Clark		
Sheet	1	of	2	Attorney Docket Number	SEDERM 3.3-010


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/ALC/	AA*	US-5,607,980-A1	04-04-1997	McAtee et al.	
/ALC/	AB*	US-3,821,372-A	06-28-1974	Vanlerberghe et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/ALC/	BA	WO-99/62478-A1	12-09-1999	Belersdorf AG		
/ALC/	BB	WO-00/62743-A2	10-26-2000	The Proctor & Gamble Company		✓
/ALC/	BC	FR-2 315 991-A	01-28-1977	L'Oreal		**
	BD	FR-1,477,048-A	04-14-1967	L'Oreal		
	BE	FR-2,091,516-A	04-14-1972	L'Oreal		TA
/ALC/	BF	WO-83/01571-A1	05-11-1983	The Regents Of The University Of California		✓
/ALC/	BG	WO-92/08685-A1	05-29-1992	L'Oreal		**
/ALC/	BH	FR-2 465 780-A	03-27-1981	L'Oreal		**
	BI	FR-2,482,128-A1	04-13-1981	L'Oreal		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/ALC/	CA	DUFRESNE et al., "Tea, Kombucha, and health: a review.", Food Research International, Vol. 33, No. 6, pgs. 409-421, 2000		
	CB	FONTANA et al., "Acetobacter Cellulose Pellicle as a Temporary Skin Substitute", Applied biochemistry and Biotechnology, Vol. 25-25, pgs. 253-64, 1990		
	CC	SADJADI, J., "Cutaneous Anthrax Associated With the Kombucha "Mushroom" in Iran.", Journal of the American Medical Association, Vol. 280, No. 18, pgs. 1567-1568, 11 November 1998		
	CD	STEINKRAUSE et al., "Investigations into the Antibiotic Activity of Tea Fungus/Kombucha Beverage", Acta Biotechnol, Vol. 16, No. 2-3, pgs. 199-205, 1996		
	CE	THORPE et al., "Role of the Maillard reaction in diabetes mellitus and diseases of aging", Drugs Aging, Vol. 9, No. 2, , pgs. 67-77, August 1996		
/ALC/	CF	NAGATAJ et al., "Protein Cross-linking by the Maillard Reaction", The journal of Biological Chemistry, Vol. 371, No. 32, pgs. 19338-19345, 1996		
	CG	FRANK, "instructions pratiques de preparation et d'utilisation"		
	CH	HAGER et al., "Hagers Handbunch der Pharmazeutischen Praxis fur Apotheker", 1973		
/ALC/	CI	BROWNLEE et al., "Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking, Vol. 232 (4758), pgs. 1269-1632, June 27, 1986		

Examiner Signature	/Amy Clark/	Date Considered	06/12/2007
-----------------------	-------------	--------------------	------------



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/523,333
				Filing Date	January 28, 2005
				First Named Inventor	Karl Lintner
				Art Unit	N/A 1655
				Examiner Name	Not Yet Assigned Amy L. Clark
Sheet	2	of	2	Attorney Docket Number	SEDERM 3.3-010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

*With English Abstract Only

1A US 3,821,372 is an English Counterpart

613469.1

Examiner Signature	/Amy Clark/	Date Considered	06/12/2007
-----------------------	-------------	--------------------	------------